<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03901989</url>
  </required_header>
  <id_info>
    <org_study_id>TOP 001-2013</org_study_id>
    <nct_id>NCT03901989</nct_id>
  </id_info>
  <brief_title>Treatment of Osteoporosis - TOP1 Clinical Study</brief_title>
  <acronym>TOP1</acronym>
  <official_title>Treatment of Osteoporosis by Panaceo: Randomized, Double-blind, Controlled, Study Assessed Effect on Bone Mineral Density and Bone Turnover of Panaceo Compared to Placebo in Osteoporotic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polyclinic K-center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Rijeka</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Polyclinic K-center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the effect of zeolite on bone mineral metabolism. The clinical
      parameters include bone mineral density, bone remodelling markers, fractures and fallings,
      the subjective evaluation of the overall health status and intensity of the musculoskeletal
      pain measured by VAS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, placebo-controlled, double-blind study. The Study lasts 12 months. Study
      Population: The study population will consist of 100 patients with osteoporosis defined
      according BMD (bone mineral density) criteria: T score -2, 5 on the femoral neck, and, or T
      -2, 5 on L1-L5, who has not been treated before, or in whom privies treatment did not been
      successful, despite a gender or age. Subjects will be randomized in each cohort to receive
      PMA-zeolite (Panaceo) or placebo (1:1). All of them will receive Vit D3 800 j daily.

      The double blind design can be reached by a &quot;third party blinding&quot; where a qualified person,
      not being involved in the assessment of the study, will administer the study treatment.

      Follow up DXA, Ca, P, ALP, Osteocalcin, Cross laps, Creatinin will be done to each subject
      before the treatment, 6 months later and after 12 months. IVA (vertebral deformity
      assessment) will be performed before the treatment and after 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 14, 2015</start_date>
  <completion_date type="Actual">March 20, 2017</completion_date>
  <primary_completion_date type="Actual">March 20, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The clinical study is a randomized, double-blinded, controlled study aimed to assess the effect of zeolite-intervention in osteoporotic patients on the bone mineral density and bone turnover in comparison to osteoporotic patients control group that received the placebo over a period of for 12 months. The study population will consist of 100 patients with osteoporosis defined according BMD criteria: T score -2, 5 on the femoral neck, and, or T -2, 5 on L1-L5, who have not been treated before, or in whom privies treatment did not been successful, despite a gender or age. The Panaceo and Placebo groups will be divided into 50 and 50 patients.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of BMD (Bone mineral density)</measure>
    <time_frame>0-6-12 months</time_frame>
    <description>BMD measurements are used to see how well osteoporosis treatments are working</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cange of Bone remodelling marker Osteocalcin</measure>
    <time_frame>0-6-12 months</time_frame>
    <description>Osteocalcin- parameter of the bone formation rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cange of Bone remodelling marker Betacross laps</measure>
    <time_frame>0-6-12 months</time_frame>
    <description>Betacross laps - parameter of the bone degradation rate</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Fractures and fallings</measure>
    <time_frame>12 months</time_frame>
    <description>Fracture: evaluation if yes) or no) Falling: Fracture as a consequence OR no fracture OR no fallings reported</description>
  </other_outcome>
  <other_outcome>
    <measure>Intensity of the musculoskeletal pain measured by VAS</measure>
    <time_frame>0-12 months</time_frame>
    <description>the scale based on patient's subjective evaluation at the beginning and at the end of the study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subjective evaluation of the overall health status and 6.</measure>
    <time_frame>0-12 months</time_frame>
    <description>upon the end of the study in comparison to the beginning</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>zeolite</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 subjects receive the substance 3 times per day as powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cellulose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50 subjects receive the substance 3 times per day as powder</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>zeolite</intervention_name>
    <description>given for a period of 12 months</description>
    <arm_group_label>zeolite</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>cellulose</intervention_name>
    <description>given for a period of 12 months</description>
    <arm_group_label>cellulose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  100 subjects with osteoporosis Among those, as a subgroup, 20 subjects with diabetes
             type 2 and osteoporosis

               -  The osteoporosis- was diagnosed by standard DXA measurement (BMD T-score: - 2.5
                  or below )

        Exclusion Criteria:

          -  chronic renal failure, secondary osteoporosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 8, 2019</study_first_submitted>
  <study_first_submitted_qc>April 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2019</study_first_posted>
  <last_update_submitted>April 2, 2019</last_update_submitted>
  <last_update_submitted_qc>April 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Polyclinic K-center</investigator_affiliation>
    <investigator_full_name>DALIBOR KRPAN</investigator_full_name>
    <investigator_title>Prof.dr.sc. Dalibor Krpan, prim.dr.med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

